• Percentage of patients maintaining average Hb concentration of 11.0-13.0g/dL throughout evaluation period. [ Time Frame: Weeks 29-36 ] [ Designated as safety issue: No ]
• Mean time spent in target Hb range; mean number of months/subject requiring any dose adjustment; RBC transfusions. [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
• AEs, laboratory parameters. [ Time Frame: Throughout study ] [ Designated as safety issue: No ]

This single arm study will assess the efficacy, safety and tolerability of subcutaneous Mircera for correction of anemia and maintenance of hemoglobin levels in patients with chronic kidney disease who are not on dialysis and are not treated with ESA. Eligible patients will receive Mircera by monthly subcutaneous injections, dependent on body weight (with a recommended starting dose of 1.2 micrograms/kg). The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

Inclusion Criteria:

• adult patients, >=18 years of age;
• chronic renal anemia, with no need for dialysis expected in next 3 months;
• adequate iron status.

Exclusion Criteria:

• previous epoetin therapy within 12 weeks prior to treatment;
• transfusion of red blood cells during 2 months prior to screening;
• significant acute or chronic bleeding such as overt gastrointestinal bleeding;
• hemolysis;
• folic acid and vitamin B 12 deficiency.